Login to Your Account



Onyx Soars as Nexavar Hits Goal in Breast Cancer Trial

By Jennifer Bogg


Thursday, July 23, 2009
Shares of Onyx Pharmaceuticals Inc. shot up 21 percent on top-line results showing that its multikinase inhibitor Nexavar met the primary endpoint in a Phase II trial, extending progression-free survival in breast cancer patients taking Xeloda. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription